Historical AI Consensus
This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.
- Symbol
- CRSP.NASDAQ
- Batch
- 7
- Published
- September 20, 2026
- AI Advisors
- 14
Historical AI Consensus Investment Thesis
CRISPR Therapeutics (CRSP) Stock Forecast and AI Rating
Forecast targets and rating
Published batch rating
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
NEUTRAL$63
+11.1%5-Year
BUY$109
+92.6%Published batch insight
Gene Editing Leader Pivots From Commercial Gestation To In Vivo Platform Compounding
High consensus confirms Casgevy commercial cash flow will steadily offset corporate research expenditures through expanding treatment centers. However, long-term valuation hinges on whether wholly owned in vivo clinical pipelines successfully navigate Phase 2 trials without encountering off-target genomic toxicity or onerous financing dilution.
This analysis preserves the original published batch. Audit published forecasts in full transparency
Sherlock Holmes (Whistleblower), Universal Investor (Polymath), Machiavelli (Insider), Superintelligence (Anthropologist), Warren Buffett (Value Purist), Elon Musk (Visionary), J.P. Morgan (Titan), Michael Burry (Vulture), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTFull published thesis
Executive Summary
If you invested $10,000 in CRISPR Therapeutics at the forecast anchor (2026-09-18): $19,260 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 58.12 | +2.76% | +2.76% | Commercial patient apheresis starts expand across authorized treatment centers, driving modest revenue gains. However, macroeconomic duration pressures and lingering skepticism regarding autologous cell processing cycle times keep valuation gains measured. |
| Q1 2027 | 58.73 | +1.06% | +3.84% | Full-year reporting exposes the divergence between partner gross therapy sales and recognized collaboration income. Net operating losses remain substantial as clinical research outlays across wholly owned pipelines absorb early commercial royalty inflows. |
| Q2 2027 | 60.53 | +3.06% | +7.02% | Pediatric label expansion conversions and finalized European reimbursement frameworks expand treatment center throughput. Operational absorption improves, allowing collaboration expense deductions to stabilize while cash burn trends moderately lower. |
| Q3 2027 | 62.84 | +3.82% | +11.11% | Presentation of mid-stage durability data for the hepatic lipid editing program demonstrates sustained biomarker knockdown. Investors begin re-evaluating the platform beyond rare hematology, lifting trading multiples despite tight broader monetary conditions. |
| Q4 2027 | 65.29 | +3.90% | +15.44% | Portfolio digestion and year-end rebalancing induce mild multiple compression. Markets weigh expanding clinical development commitments against ongoing autologous manufacturing bottlenecks, prompting tactical consolidation around baseline balance sheet cash support. |
| Q1 2028 | 66.36 | +1.64% | +17.33% | Pediatric infusion volume gains across North America improve commercial program cash generation. Vertex collaboration receipts begin visibly dampening corporate cash burn, reinforcing investor confidence in balance sheet durability. |
| Q2 2028 | 70.00 | +5.48% | +23.76% | Advancement of wholly owned in vivo assets into larger clinical cohorts drives pipeline valuation gains. Steady commercial revenue execution counters broader macroeconomic tightness, supporting constructive institutional accumulation. |
| Q3 2028 | 72.36 | +3.37% | +27.94% | Casgevy achieves operational cash breakeven within the joint collaboration structure. The removal of partnership cash drag allows non-dilutive balance sheet interest income to effectively buffer internal clinical research expenditures. |
| Q4 2028 | 74.61 | +3.11% | +31.92% | Increased clinical spending required for concurrent Phase 2 cardiometabolic trials temporarily widens quarterly net losses. Investors balance the heavy investment intensity against encouraging long-term pipeline biomarker durability. |
| Q1 2029 | 77.14 | +3.39% | +36.39% | Annual financial results demonstrate sustained reduction in operating cash burn as global commercial therapy adoption broadens. Long-term fundamental value seekers accumulate shares, recognizing the transition toward commercial self-funding. |
| Q2 2029 | 80.50 | +4.36% | +42.33% | Potential non-dilutive licensing arrangements or co-development partnerships for wholly owned clinical assets inject fresh balance sheet capital. Strategic optionality validates proprietary lipid nanoparticle delivery platforms across cardiometabolic cohorts. |
| Q3 2029 | 83.24 | +3.40% | +47.17% | International reimbursement milestones across mature markets deliver stable recurring royalty distributions. The stock demonstrates resilient relative performance as research automation and clinical prioritization optimize operational productivity. |
| Q4 2029 | 86.71 | +4.17% | +53.30% | Clinical progression in allogeneic immunology programs demonstrates multi-disease platform utility. Steady commercial execution offsets minor sector multiple compression stemming from persistent high risk-free interest rates. |
| Q1 2030 | 90.10 | +3.91% | +59.29% | Casgevy collaboration cash flow reaches meaningful operational contribution, fully funding corporate general overhead. Institutional growth capital reweights toward the equity as commercial longevity dispels early adoption skepticism. |
| Q2 2030 | 91.86 | +1.96% | +62.42% | Registration-enabling clinical data for proprietary hepatic editing programs approach completion. The prospect of broad cardiometabolic market access expands forward enterprise value multiples across Wall Street models. |
| Q3 2030 | 95.91 | +4.41% | +69.58% | Commercial cell therapy reaches mature steady-state adoption in Western jurisdictions. Steady cash distributions provide a dependable fundamental floor while investors await registrational filing packages for in vivo assets. |
| Q4 2030 | 99.04 | +3.26% | +75.11% | Preparations for regulatory submissions and commercial manufacturing infrastructure for systemic in vivo assets cause minor margin digestion, keeping equity performance orderly heading into fiscal year-end. |
| Q1 2031 | 101.80 | +2.79% | +79.99% | Resolution of the convertible senior notes maturity via equity conversion eliminates debt repayment overhang. The clarified capital structure and diluted share count establish a stable foundation for long-term equity compounding. |
| Q2 2031 | 105.21 | +3.35% | +86.02% | Priority regulatory reviews for wholly owned systemic gene editing candidates expand addressable market visibility. The company establishes clear technical leadership across both ex vivo cell and in vivo genetic medicines. |
| Q3 2031 | 108.93 | +3.54% | +92.60% | Commercial launches for next-generation therapies alongside mature global Casgevy cash flows complete the transformation into a multi-product biopharmaceutical platform, securing strong terminal enterprise valuation. |
CRISPR Therapeutics is navigating a pivotal corporate evolution from an ex vivo cellular engineering pioneer into a diversified, multi-product genomic medicine platform. Market participants mischaracterize early Casgevy performance as a launch failure, failing to account for the structural eight-to-twelve-month lag inherent in autologous cell mobilization, quality validation, and myeloablative conditioning. As Qualified Treatment Centers scale globally and pediatric label expansions take effect, CRISPR's 40% net collaboration profit share will shift from an operational expense drag toward a positive cash flow stream. Concurrently, wholly owned systemic in vivo programs—principally CTX310 targeting ANGPTL3—are demonstrating durable multi-lipid knockdown in human clinical cohorts, validating non-viral lipid nanoparticle delivery and de-risking a cardiometabolic market orders of magnitude larger than rare hematology niches. Valuation sensitivity remains tightly linked to macroeconomic cost-of-capital pressures and clinical safety margins. Holding approximately $2.36 billion in cash, cash equivalents, and marketable securities provides a resilient multi-year operational runway, fully insulating development from distressed equity refinancing while the March 2031 convertible senior notes dictate prospective share-count dilution.
Key insights
- Casgevy accounting reflects a substantial lead-lag mismatch where over 500 patient initiations generate trailing collaboration revenue only after completing protracted conditioning protocols.
- In vivo hepatic editing transforms the platform from artisanal patient-specific transplant manufacturing into scalable, off-the-shelf outpatient infusions with superior gross margins.
- Convertible debt obligations and heavy Phase 2/3 trial reinvestment consume liquidity, making non-dilutive biopharma partnerships essential to preserve equity ownership per share.
CRISPR Therapeutics is moving from lab research to commercial reality. Its approved gene therapy, Casgevy, takes several months to manufacture and requires difficult chemotherapy preparation, which has slowed early revenue. However, as specialized hospitals gain experience and younger patients become eligible, sales will ramp up. The company keeps 40% of the profits from its partner Vertex, which will gradually cover research costs. Meanwhile, its next-generation therapies aim to treat common heart conditions with simple, one-time injections rather than complex cell transplants. Backed by over $2.3 billion in cash, the company can fund its clinical trials for years without needing emergency loans.
Key insights
- Lengthy patient cell processing creates temporary revenue delays that hide strong underlying commercial demand from specialized hospitals.
- Wholly owned liver-editing programs offer much larger patient populations and cheaper manufacturing than personalized cell transplants.
- Pristine cash reserves eliminate bankruptcy danger, but advancing multiple clinical trials will require strict capital discipline to avoid dilution.
Deep Dive
Prevailing market consensus views CRISPR Therapeutics as an uncommercialized clinical pioneer burdened by an agonizingly slow Casgevy rollout and an annual cash burn approaching half a billion dollars. Investors dwell on busulfan conditioning toxicity, complex manufacturing cycles, and tight Medicaid budgets. High interest rates further penalize long-duration biotech pipelines, causing markets to treat in vivo assets as speculative lottery tickets.